166 related articles for article (PubMed ID: 23337383)
1. A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium.
Jordan I; Horn D; John K; Sandig V
Viruses; 2013 Jan; 5(1):321-39. PubMed ID: 23337383
[TBL] [Abstract][Full Text] [Related]
2. A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA).
Jordan I; Horn D; Thiele K; Haag L; Fiddeke K; Sandig V
Virol Sin; 2020 Apr; 35(2):212-226. PubMed ID: 31833037
[TBL] [Abstract][Full Text] [Related]
3. Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.
Jordan I; Lohr V; Genzel Y; Reichl U; Sandig V
Microorganisms; 2013 Nov; 1(1):100-121. PubMed ID: 27694766
[TBL] [Abstract][Full Text] [Related]
4. Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells.
Peng C; Moss B
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3759-3767. PubMed ID: 32019881
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous and Targeted Mutations in the Decapping Enzyme Enhance Replication of Modified Vaccinia Virus Ankara (MVA) in Monkey Cells.
Erez N; Wyatt LS; Americo JL; Xiao W; Moss B
J Virol; 2021 Sep; 95(19):e0110421. PubMed ID: 34232734
[TBL] [Abstract][Full Text] [Related]
6. High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.
Vázquez-Ramírez D; Jordan I; Sandig V; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2019 Apr; 103(7):3025-3035. PubMed ID: 30796494
[TBL] [Abstract][Full Text] [Related]
7. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.
Meisinger-Henschel C; Späth M; Lukassen S; Wolferstätter M; Kachelriess H; Baur K; Dirmeier U; Wagner M; Chaplin P; Suter M; Hausmann J
J Virol; 2010 Oct; 84(19):9907-19. PubMed ID: 20668072
[TBL] [Abstract][Full Text] [Related]
8. SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.
Liu R; Mendez-Rios JD; Peng C; Xiao W; Weisberg AS; Wyatt LS; Moss B
PLoS Pathog; 2019 May; 15(5):e1007710. PubMed ID: 31145755
[TBL] [Abstract][Full Text] [Related]
9. Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara.
Jordan I; Horn D; Oehmke S; Leendertz FH; Sandig V
Virus Res; 2009 Oct; 145(1):54-62. PubMed ID: 19540275
[TBL] [Abstract][Full Text] [Related]
10. High-cell-density cultivations to increase MVA virus production.
Vázquez-Ramírez D; Genzel Y; Jordan I; Sandig V; Reichl U
Vaccine; 2018 May; 36(22):3124-3133. PubMed ID: 29433897
[TBL] [Abstract][Full Text] [Related]
11. Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production.
Gränicher G; Tapia F; Behrendt I; Jordan I; Genzel Y; Reichl U
Biotechnol J; 2021 Jan; 16(1):e2000024. PubMed ID: 32762152
[TBL] [Abstract][Full Text] [Related]
12. Preparation of Cell Cultures and Vaccinia Virus Stocks.
Cotter CA; Earl PL; Wyatt LS; Moss B
Curr Protoc Protein Sci; 2017 Aug; 89():5.12.1-5.12.18. PubMed ID: 28762495
[TBL] [Abstract][Full Text] [Related]
13. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.
Hornemann S; Harlin O; Staib C; Kisling S; Erfle V; Kaspers B; Häcker G; Sutter G
J Virol; 2003 Aug; 77(15):8394-407. PubMed ID: 12857909
[TBL] [Abstract][Full Text] [Related]
14. In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate.
Okeke MI; Nilssen Ø; Moens U; Tryland M; Traavik T
Virol J; 2009 May; 6():55. PubMed ID: 19435511
[TBL] [Abstract][Full Text] [Related]
15. An avian cell line designed for production of highly attenuated viruses.
Jordan I; Vos A; Beilfuss S; Neubert A; Breul S; Sandig V
Vaccine; 2009 Jan; 27(5):748-56. PubMed ID: 19071186
[TBL] [Abstract][Full Text] [Related]
16. Preparation of Cell Cultures and Vaccinia Virus Stocks.
Cotter CA; Earl PL; Wyatt LS; Moss B
Curr Protoc Microbiol; 2015 Nov; 39():14A.3.1-14A.3.18. PubMed ID: 26528781
[TBL] [Abstract][Full Text] [Related]
17. Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells.
Peng C; Wyatt LS; Glushakow-Smith SG; Lal-Nag M; Weisberg AS; Moss B
PLoS Pathog; 2020 Aug; 16(8):e1008845. PubMed ID: 32866210
[TBL] [Abstract][Full Text] [Related]
18. Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages.
Neckermann P; Mohr M; Billmeier M; Karlas A; Boilesen DR; Thirion C; Holst PJ; Jordan I; Sandig V; Asbach B; Wagner R
Front Immunol; 2024; 15():1338492. PubMed ID: 38380318
[TBL] [Abstract][Full Text] [Related]
19. The EB66® cell line as a valuable cell substrate for MVA-based vaccines production.
Léon A; David AL; Madeline B; Guianvarc'h L; Dureau E; Champion-Arnaud P; Hebben M; Huss T; Chatrenet B; Schwamborn K
Vaccine; 2016 Nov; 34(48):5878-5885. PubMed ID: 27997338
[TBL] [Abstract][Full Text] [Related]
20. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
